Wang Q, Altermatt H J, Ris H B, Reynolds B E, Stewart J C, Bonnett R, Lim C K
MRC Toxicology Unit, Medical Research Council Laboratories, Carshalton, Surrey, UK.
Biomed Chromatogr. 1993 May-Jun;7(3):155-7. doi: 10.1002/bmc.1130070311.
A procedure for the extraction and high performance liquid chromatographic (HPLC) determination of the photodynamic therapeutic agent 5,10,15,20-tetra(m-hydroxyphenyl)chlorin in human, rat and mouse tissues following intravenous administration of the drug is described. The tissue (tumour, skin, muscle and liver) was homogenized and extracted into a mixture of methanol:dimethyl sulphoxide:water (32:8:1 by vol.) containing, 5,10,15,20-tetra(p-hydroxyphenyl)chlorin as the internal standard. The precipitated proteins were removed by centrifugation and the supernatant was separated by reversed phase HPLC on a Hypersil-ODS column with 77% (v/v) acetonitrile in 0.1% trifluoroacetic acid as the mobile phase. The solute was detected with high sensitivity and specificity by a UV-VIS detector set at 423 nm.
描述了一种在静脉注射药物后，从人、大鼠和小鼠组织中提取并通过高效液相色谱（HPLC）测定光动力治疗剂5,10,15,20-四（间羟基苯基）二氢卟酚的方法。将组织（肿瘤、皮肤、肌肉和肝脏）匀浆后，用含有5,10,15,20-四（对羟基苯基）二氢卟酚作为内标的甲醇：二甲基亚砜：水（体积比为32:8:1）混合物进行提取。通过离心去除沉淀的蛋白质，上清液在Hypersil-ODS柱上进行反相HPLC分离，流动相为含0.1%三氟乙酸的77%（v/v）乙腈。用设置在423nm的紫外-可见检测器以高灵敏度和特异性检测溶质。
